Google AI
The Times Australia

Times Media Advertising

Zuellig Pharma unveils state-of-the-art Clinical Trial Support Innovation Center in South Korea to support both domestic and global clinical research needs

New facility is set to be South Korea’s most advanced automated hub for clinical logistics and sourcing, reinforcing the nation’s position as a leader in clinical research innovation

GYEONGGI-DO, SOUTH KOREA - Media OutReach Newswire - 1 December 2025 - Zuellig Pharma, a leading healthcare solutions company in Asia, today announced the grand opening of its new state-of-the-art Clinical Trial Support (CTS) Innovation Center in South Korea.

The opening of this facility underscores Zuellig Pharma's continued investment and commitment to advancing healthcare, reinforcing its position as a trusted regional partner in driving meaningful outcomes for patients, partners, and communities across the region.

Strategically located near the Gyeongbu Expressway in Gyeonggi-do province, the new 3,800-square-meter facility is set to redefine standards in clinical trial logistics through automation, digitalization, and stringent Good Practice (GxP) compliance. It is designed to enhance operational efficiency, scalability, and reliability across diverse therapeutic areas.

"As part of an integrated healthcare solutions company, this milestone marks a significant step forward for Zuellig Pharma in remaining agile and responsive to the evolving clinical trial landscape. It also reflects Zuellig Pharma's continued commitment to advancing healthcare through innovation and sustainable infrastructure, creating greater access to treatments and delivering meaningful outcomes for partners and communities we serve," said John Graham, CEO of Zuellig Pharma.

The facility is equipped with advanced capabilities that set new standards for clinical trial logistics. It features a fully automated order fulfillment system that enhances the speed, accuracy, and reliability of clinical supply delivery. Its flexible and scalable architecture ensures uninterrupted operations, while robust cybersecurity measures safeguard sensitive clinical trial data.

In addition, the facility provides comprehensive temperature-zone support, enabling Zuellig Pharma to manage thousands of unique clinical trial SKUs under strict ambient, cold, frozen, deep frozen, cryogenic and return storage conditions. This ensures that temperature-sensitive products are handled with the highest level of precision throughout the entire supply chain.

Designed with precision, the facility's specialized repackaging infrastructure is built to accommodate controlled environments tailored to ambient, cold, frozen, and amber light repackaging specifications. These environments meet stringent clinical and regulatory standards, ensuring product integrity is maintained throughout the clinical trial lifecycle. Furthermore, an integrated end-to-end tracking and monitoring system provides full chain-of-custody, complete traceability, and adherence to GxP requirements, reinforcing quality and compliance at every stage.

"As of 2025, South Korea ranks among the world's top 10 clinical trials markets and holds the third-largest number of R&D pipelines globally. Our new facility has been built to meet this rising demand, redefining how investigational products are stored, managed, and distributed. With precision in mind, we aim to enable the reliable delivery of critical therapies to improve patient access and outcomes worldwide," added Giuseppe Leo, SVP, Clinical Trial Support Business Unit Lead, Zuellig Pharma.

Over the past year, the center has supported over 3,000 cumulative studies in collaboration with more than 100 clients, managing an annual volume of approximately 13,000 outbound shipments, including chemical, biologics, medical devices and cellular and gene therapies. Its extensive track record includes partnerships with 14 of the world's top 20 pharmaceutical companies and 8 of the top 10 global CROs, underscoring its position as a trusted partner in global clinical trial research.

Hashtag: #ZuelligPharma #ClinicalTrials #Automation #Healthcare #Pharmaceuticals #ColdChain #Logistics



The issuer is solely responsible for the content of this announcement.

About Zuellig Pharma

Zuellig Pharma is a leading healthcare solutions company in Asia, and our purpose is to make healthcare more accessible to the communities we serve. We provide world-class distribution, commercialization, and clinical trial support services, underpinned by a strong culture of innovation to support the growing healthcare needs in this region. The company was founded a hundred years ago and has grown to become a multibillion-dollar business covering 18 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.

Times Magazine

The Human Supplement Craze Has Officially Gone to the Dogs (Literally)

Australians’ appetite for supplements is no longer limited to their own vitamin cabinets. New reta...

AI Guilt: It’s Real — But it is irrational

Artificial intelligence is rapidly becoming one of the most powerful tools ever made available to ...

Australians Are Keeping Their Cars Longer — And It’s Changing The Market

Australia’s car market is undergoing a subtle but important transformation. People are keeping th...

Streaming Fatigue: Australians Overwhelmed By Subscriptions

Streaming was once supposed to simplify entertainment. Instead, many Australians now feel overwhe...

Why Shopping Centres No Longer Feel Exciting

There was a time when going to the shopping centre felt like an event. Families spent entire Satu...

Harry And Meghan: Less Powerful As Royals, More Powerful As Content

For all the claims of “Harry and Meghan fatigue”, the world’s media still cannot stop talking abou...

The Times Features

The Biden Administration: Did The Inquiry Establish Who…

Questions surrounding former US President Joe Biden and his health while in office continue to dom...

Nationals move Bill to protect women. Sall Grover inter…

Matt Canavan  All good. Look, well, it's great to be here with my friend and colleague, Alison Pe...

The Human Supplement Craze Has Officially Gone to the D…

Australians’ appetite for supplements is no longer limited to their own vitamin cabinets. New reta...

The Teals: Can They Spoil Australia’s New Attraction to…

Australian politics is shifting again. For years, the dominant national contest revolved around L...

Property Paralysis: Buyers Hesitate As Australia’s Hous…

Australia’s property market may still be active, but beneath the auctions, listings and glossy rea...

The Return Of Practical Luxury: Buyers Want Quality Aga…

For years, consumer culture revolved around speed and abundance. Fast fashion.Fast furniture.Fast...

People Are Going Out Less — And Businesses Know It

Restaurants are full on some nights. Concerts still sell tickets. Sporting events attract crowds. ...

Why Shopping Centres No Longer Feel Exciting

There was a time when going to the shopping centre felt like an event. Families spent entire Satu...

The Liberal Party Faces Its Greatest Question Since Men…

When Robert Menzies founded the Liberal Party of Australia in the aftermath of World War II, Austr...